These drugs initially came to market for diabetes and we have since added obesity, sleep apnea and fatty liver to the list of indications and we expect many more formally recognized indications to follow
Notably, Nicolau et al 8 reported a significant PASI reduction from 10 to 5.1 and DLQI improvement from 12.7 to 6.4 in patients with obesity without diabetes treated with liraglutide
Specter SC, Klein TW, Newton C, Mondragon M, Widen R, Friedman H
While C-reactive protein (CRP) is the most established systemic inflammatory CV risk marker, recent data indicate that inflammatory markers in vascular tissue [matrix metalloproteinases (MMP), osteopontin (OPN), and cathepsin D] may be more specific measures of plaque instability (239)
You shouldnt use it long-term unless directed to do so by a healthcare professional
Always verify with your pharmacy